



GlaxoSmithKline Pharmaceuticals Limited  
 GSK House, Dr. Annie Besant Road,  
 Worli, Mumbai - 400 030  
 Tel No: +91 22 2495 9595  
 Fax No: +91 22 2495 9494  
 Web: [www.gsk-india.com](http://www.gsk-india.com)  
 Email: [askus@gsk.com](mailto:askus@gsk.com)

22<sup>nd</sup> March, 2024

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
 Dalal Street  
 Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
 Bandra-Kurla Complex, Bandra (East)  
 Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India  
 (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received a below mentioned orders.

- Final Order from the ACIT Cir 7(1)(1) with the Demand Liability of Rs 19.45 Crores. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	DCIT issued the Assessment Order (under faceless Assessment) u/s 143(3) r.w. Section 144C (3) for the AY 2022-2023.
2	Nature and details of the action(s) taken, initiated or order(s) passed	Demand raised for INR 7.22/- Crores after disallowing a few expenses for the GSK AY: 2022-2023.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	22 <sup>nd</sup> March, 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	Few Expenses incurred for HCP/Doctor and Physician Samples Expenses are disallowed.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	At present, there is no impact on GSK as this is a Legacy issue for GSK under litigation for the past years. GSK will be going to file a further appeal at the 1 <sup>st</sup> appellate authority. challenging the Assessing Officer Order.

- Company has received an Order dated 20<sup>th</sup> March 2024 from Haryana GST authorities, disallowing certain GST credits in Haryana State. The relevant details to be is disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Assistant Commissioner of GST, 26/615, Manav Chowk, Ambala
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 20 <sup>th</sup> March 2024 passed under Section 74 of CGST Act, 2017 for Tax of Rs.46,61,258 along with applicable interest and Penalty of Rs.46,52,194, aggregating to demand of Rs.93,22,516 for FY18-19 in Haryana State.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	21 <sup>st</sup> March 2024

4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand for FY 2018-19 on account of difference in GST credit mismatch between Company's GST returns and details reported by vendors in their GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company believes that the said demand is not maintainable and will be filing an Appeal against the said Order.

- Company has received an Order dated 14<sup>th</sup> March 2024 from Tamil Nadu GST and Central Excise authorities, disallowing certain GST credits in Tamil Nadu State. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Deputy Commissioner of GST and Central Excise, Poonamallee Division – Chennai Outer Commissionerate.
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 4 March 2024 passed under Section 73 of CGST Act, 2017 for Tax of Rs.6,90,266 along with applicable interest and Penalty of Rs.89,620, aggregating to demand of Rs.7,79,886 for FY18-19 in Tamil Nadu State.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	14 <sup>th</sup> March 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand for FY 2018-19 on account of difference in GST credit mismatch between Company's GST returns and details reported by vendors in their GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company believes that the said demand is not maintainable and will be filing an Appeal against the said Order

Note – The delay in communication of this Order is due to delay in receipt of summary Order from GST authorities.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151